Dicerna Pharmaceuticals Obtains $60,000,000 Series C Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=69957a00-4837-4ba6-a5ab-e97f957e6204 - Date
8/1/2013 - Company Name
Dicerna Pharmaceuticals - Mailing Address
480 Arsenal Street Watertown, MA 02472 - Company Description
Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism. - Website
http://www.dicerna.com - Transaction Type
Venture Equity - Transaction Amount
$60,000,000 - Transaction Round
Series C - Proceeds Purposes
Proceeds from the financing will be used to advance two or more programs into the clinic and to progress other preclinical programs. The company also plans to use the proceeds to continue to develop innovative drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties allowing for direct delivery into specific cells of interest. - M&A Terms
- Venture Investor
RA Capital - Venture Investor
Brookside Capital - Venture Investor
Deerfield Capital - Venture Investor
Omega Funds - Venture Investor
Abingworth Management - Venture Investor
Domain Associates - Venture Investor
Oxford Bioscience Partners - Venture Investor
Skyline Ventures - Venture Investor
SR One
